Clinical study validating PTRA test published

AI SummaryClose X

Verici Dx Plc announced the publication of a peer-reviewed clinical validation study for its Pre-Transplant Rejection Assessment (PTRA) test in Kidney360, demonstrating its superior ability to predict early acute rejection in kidney transplant recipients compared to conventional methods. This advancement allows for safer minimization of immunosuppressive therapy by identifying low-risk patients, addressing a significant unmet need in transplant medicine and potentially reducing risks associated with over-suppression such as toxicity, infections, and malignancy. The PTRA test is commercially marketed by Thermo Fisher Scientific.

Disclaimer*

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings